CTOs on the Move

Viridian Therapeutics

www.viridianbio.com

 
Viridian Therapeutics focuses in advancing new treatments for patients with diseases that are underserved by today`s therapies.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Viridian Therapeutics raised $27M on 09/29/2020

Similar Companies

Micromet

Micromet, Inc is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Remel Inc

Remel Inc is a Lenexa, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Truvian Health

Truvian is a healthcare company at the intersection of diagnostics and consumer tech. We are disrupting the blood testing industry by developing an automated, benchtop diagnostic system to provide lab-accurate results in 20 minutes for a comprehensive suite of health tests. Our proprietary approach, for which we are seeking FDA clearance, is intended to fulfill the promise of delivering accessible and affordable blood testing from one small blood sample, in minutes, in a retail setting or private clinic.

Regenxbio

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO`s NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO`s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO`s NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.

Icosavax

Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. The company was founded on breakthrough computationally-designed virus like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington. Icosavax is located in Seattle.